Enacting the Kansas pharmacy services administrative organization act.
HB 2551 creates the Kansas pharmacy services administrative organization act and places pharmacy services administrative organizations (PSAOs) under regulation by the commissioner of insurance. The bill defines PSAOs as entities that negotiate and provide administrative services for independent pharmacies in dealings with pharmacy benefits managers (PBMs) and third-party payers, and it requires PSAOs operating in Kansas to obtain a license from the Department of Insurance. The licensing process would include ownership and control disclosures, identification of beneficial owners and managers, and background information regarding felony convictions or legal violations related to pharmacy administration or PBM activity.
The bill also imposes ongoing disclosure and contract requirements. PSAOs would have to disclose ownership or control information to the department and to contracting pharmacies, PBMs, and third-party payers, and update those disclosures when material changes occur. Contracts would need to address timely delivery of contract documents, remittance pass-through, audit-related information sharing, appeal handling, and notice procedures. The bill further restricts certain business practices, such as requiring pharmacies to buy specified drug quantities to obtain discounts, discriminating on drug pricing based on wholesale purchase prices, and conditioning contracts on purchases from affiliated suppliers in certain ownership situations.
HB 2551 would add a new regulatory framework to Kansas insurance law for PSAOs, expanding the commissioner of insurance’s oversight authority over entities that mediate between independent pharmacies and PBMs or other payers. It would create licensing, disclosure, contract, audit, appeal, and anti-affiliation provisions, and violations would be treated as unfair trade practices, subject to daily penalties and possible license revocation or nonrenewal. The bill would also authorize the commissioner to adopt implementing rules by January 1, 2027.
Based on the bill text and the absence of recorded committee testimony or votes, the overall posture of the bill appears regulatory and protective of independent pharmacies rather than overtly partisan. The measure is framed as increasing transparency, accountability, and fair dealing in pharmacy contracting and PBM-related transactions. Because there are no transcripts or recorded votes provided, there is no documented opposition or support to characterize beyond the bill’s apparent policy intent.
The main points of potential contention are the bill’s new licensing and reporting burdens on PSAOs, the confidentiality treatment of submitted information, and the restrictions on affiliated ownership and purchasing arrangements. Independent pharmacies are likely the primary beneficiaries of the bill’s protections, while PSAOs, PBMs, and vertically integrated drug or device companies may view the requirements as limiting contracting flexibility and increasing compliance costs. The bill also raises practical questions about how audits, appeals, and remittance timing would be administered under the new statutory framework.